1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
3.8. Product Pipeline
4. TECHNOLOGICAL OUTLOOK
5. GLOBAL REGENERATIVE DRUGS MARKET BY TYPE
5.1. Introduction
5.2. Stem Cell Therapy
5.3. Gene Therapy
5.4. Tissue Engineering
5.5. Others
6. GLOBAL REGENERATIVE DRUGS MARKET BY MATERIAL
6.1. Introduction
6.2. Biodegradable Polymers
6.3. Ceramics
6.4. Hydrogels
6.5. Others
7. GLOBAL REGENERATIVE DRUGS MARKET BY APPLICATION
7.1. Introduction
7.2. Cardiovascular
7.3. Oncology
7.4. Dermatology & Wound Care
7.5. Musculoskeletal
7.6. Ophthalmology
7.7. Neurology
7.8. Others
8. GLOBAL REGENERATIVE DRUGS MARKET BY END-USER
8.1. Introduction
8.2. Hospitals
8.3. Biomedical Laboratories
8.4. Academic & Research Centers
9. GLOBAL REGENERATIVE DRUGS MARKET BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. USA
9.2.2. Canada
9.2.3. Mexico
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Others
9.4. Europe
9.4.1. Germany
9.4.2. France
9.4.3. United Kingdom
9.4.4. Italy
9.4.5. Spain
9.4.6. Others
9.5. Middle East and Africa
9.5.1. Saudi Arabia
9.5.2. UAE
9.5.3. Israel
9.5.4. Others
9.6. Asia Pacific
9.6.1. China
9.6.2. Japan
9.6.3. India
9.6.4. South Korea
9.6.5. Thailand
9.6.6. Taiwan
9.6.7. Indonesia
9.6.8. Others
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Market Share Analysis
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard
11. COMPANY PROFILES
11.1. Allogene Therapeutics, Inc.
11.2. Atara Biotherapeutics, Inc.
11.3. CollPlant Biotechnologies Ltd.
11.4. CRISPR Therapeutics AG
11.5. Editas Medicine, Inc.
11.6. Gamida Cell Ltd.
11.7. Poseida Therapeutics, Inc (Roche)
11.8. Novartis AG
11.9. Gilead Sciences, Inc.
11.10. Bristol-Myers Squibb Company
11.11. Pfizer Inc.
11.12. Organogenesis Holdings Inc.
11.13. Smith+Nephew
12. APPENDIX
12.1. Currency
12.2. Assumptions
12.3. Base and Forecast Years Timeline
12.4. Key benefits for the stakeholders
12.5. Research Methodology
12.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES